JNJ: Oncology Pipeline Sale Plans And Talc Cases Will Shape Future Risk

The analyst price target for Johnson & Johnson has been raised by $1 to $232.50, as analysts factor in slightly higher revenue growth expectations, a modest adjustment to profit margin assumptions, and an updated future P/E of 25.94 following a series of recent target increases and an upgrade from major firms.

Analyst Commentary

Recent Street research on Johnson & Johnson has leaned positive, with several firms lifting price targets and one issuing an upgrade, while a smaller group of voices remains more cautious on how much upside is already reflected in the valuation.

Bullish Takeaways

Bullish analysts are framing the higher targets as a reset to reflect the updated future P/E of 25.94, suggesting they see that multiple as reasonable given their expectations for execution and earnings visibility.
Several price target increases, including moves of $13, $15, $18, $28 and $35, signal that optimistic analysts see more room between the current share price and their assessment of fair value, rather than a market that has already fully priced in their growth assumptions.
The recent upgrade at a major brokerage is being viewed as confirmation that at least some large research desks are more comfortable with Johnson & Johnson's positioning and earnings trajectory than they were previously.
At least one analyst lifting a target to $208 from $193 shows a willingness to nudge fair value higher even while keeping a more neutral rating, which can be read as confidence in the company’s ability to execute without relying on aggressive multiple expansion.

Bearish Takeaways

Even with higher targets, some analysts are holding back from outright bullish ratings, which suggests they see the risk of the stock already trading close to their fair value ranges if execution or growth comes in below expectations.
The wide spread between more modest target moves, such as $1 to $6, and the larger increases in the mid to high teens and above, indicates that there is still disagreement on how much earnings power Johnson & Johnson should be credited with in the current P/E.
Analysts maintaining Market Perform style stances alongside target increases indicate a view that upside could be more incremental than dramatic, with limited room for error on both earnings delivery and valuation support.
The clustering of multiple target revisions in a short window can also reflect a catch up effect, where analysts are aligning models with peers, which may reduce the margin of safety for investors if sentiment cools or assumptions are revised again.

What's in the News

Johnson & Johnson is preparing a potential sale of its DePuy Synthes orthopedics unit, with reports suggesting the business could be valued at more than US$20b and has attracted interest from several large private equity firms and possible industry buyers, after previously considering a spinoff of the unit (Bloomberg).
A Baltimore jury ordered Johnson & Johnson and related entities to pay more than US$1.5b to a plaintiff in a talc related mesothelioma case, described as one of the largest single plaintiff verdicts against the company. This highlights ongoing legal exposure around historical talc products (Reuters).
Separate jury verdicts in Pennsylvania, Minnesota and California awarded US$250,000, US$65.5m and US$40m respectively in cases alleging talc based products contributed to ovarian cancer or mesothelioma. These outcomes reinforce the scale and continuity of talc related litigation risk for Johnson & Johnson.
Bayer filed suit against Johnson & Johnson and Janssen Biotech in U.S. federal court, alleging that J&J used a real world evidence analysis with methodological flaws to promote ERLEADA in prostate cancer and that the claims mislead healthcare providers in violation of the Lanham Act.
On the pharmaceutical side, Johnson & Johnson reported multiple product and pipeline updates, including FDA approvals and new clinical data across oncology, immunology and neuroscience. These updates expand the information set investors can use to assess the role of newer drugs and platforms within the broader business mix.

Valuation Changes

Fair Value: Adjusted from $231.25 to $232.50, an upward change of about 0.5%.
Discount Rate: Held steady at 6.98% in the updated model.
Revenue Growth: Increased from 6.04% to 6.12%, reflecting a slightly higher long term revenue growth assumption.
Net Profit Margin: Reduced from 23.65% to 23.60%, indicating a small decrease in the margin assumption.
Future P/E: Raised from 25.73x to 25.94x, representing a modest increase in the valuation multiple applied to earnings.

Johnson & Johnson is poised for growth in immunology and oncology despite facing challenges from loss of drug exclusivity, leveraging next-gen therapies for strengthened revenue.
Strategic investments in U.S. operations, acquisitions, and MedTech expansion aim to boost future earnings and efficiency, with potential restructuring in surgery to aid profitability.
Loss of exclusivity for key products and tariffs could significantly threaten revenue and margins, while ongoing litigation poses financial risks.

Catalysts

About Johnson & Johnson

Engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide.What are the underlying business or industry changes driving this perspective?

Johnson & Johnson anticipates accelerated growth in their portfolio and pipeline, particularly in the Innovative Medicine sector, despite the headwind from STELARA's loss of exclusivity. This is expected to bolster revenues through next-generation therapies and significant market share gains in oncology and immunology.
The company's substantial investment of over $55 billion into manufacturing, R&D, and technology in the U.S. over the next four years is projected to expand capacity for advanced medicines and devices, potentially increasing operational efficiency and future earnings.
Recent acquisitions, such as Intra-Cellular Therapies, are expected to contribute substantial revenue streams, with products like CAPLYTA potentially reaching over $5 billion in peak sales, positively affecting the company’s revenue and EPS in the future.
Ongoing expansion within MedTech, highlighted by strong performance from acquired cardiovascular units Abiomed and Shockwave, as well as developments in robotic surgery, are expected to drive revenue growth and enhance adjusted income margins over time.
The company plans significant restructuring in their surgery business within MedTech to streamline operations and improve efficiency, anticipated to have short-term revenue disruptions but expected to enhance long-term profitability and margin expansion.

Johnson & Johnson Earnings and Revenue Growth

Johnson & Johnson Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Johnson & Johnson's revenue will grow by 4.7% annually over the next 3 years.
Analysts assume that profit margins will shrink from 25.0% today to 22.0% in 3 years time.
Analysts expect earnings to reach $22.9 billion (and earnings per share of $10.07) by about September 2028, up from $22.7 billion today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $19.1 billion.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 22.8x on those 2028 earnings, up from 18.8x today. This future PE is greater than the current PE for the US Pharmaceuticals industry at 19.0x.
Analysts expect the number of shares outstanding to remain consistent over the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.78%, as per the Simply Wall St company report.

Johnson & Johnson Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Loss of exclusivity for STELARA and the impact of biosimilar competition could significantly erode revenue from one of Johnson & Johnson's major products. This could affect overall revenue and net margins, especially in the innovative medicine segment.
Tariffs, particularly those related to exports to China, could increase costs and impact the net margins negatively, due to increased cost of goods sold from tariffs being relieved through the P&L in future periods.
The ongoing litigation related to talc, though controlled for now, poses a continual risk to financial stability and could impact net earnings and cash flow, particularly if adverse judgments or settlements occur.
The orthopedics segment faced headwinds, including competitive pressures and challenges in the spine and sports areas. Ongoing issues could impact revenue and earnings unless the planned innovations drive a turnaround.
Potential dilution from acquisitions such as Intra-Cellular Therapies and the impact of tariffs could affect operating margin improvement efforts, challenging overall earnings and net margins despite robust sales growth in some areas.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $177.468 for Johnson & Johnson based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $200.0, and the most bearish reporting a price target of just $155.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $104.1 billion, earnings will come to $22.9 billion, and it would be trading on a PE ratio of 22.8x, assuming you use a discount rate of 6.8%.
Given the current share price of $176.96, the analyst price target of $177.47 is 0.3% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Johnson & Johnson?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.